Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]
Latest Information Update: 19 Sep 2023
At a glance
- Drugs BMS 986178 (Primary) ; BMS 986178 (Primary) ; Nelitolimod (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 28 May 2021 Planned End Date changed from 12 Jun 2022 to 12 Jun 2023.
- 28 May 2021 Planned primary completion date changed from 12 Jun 2022 to 3 Mar 2023.